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INTRODUCTION 
 
 
       The hemodynamic responses to laryngoscopy and endotracheal 
intubation have been recognised since 1951. The induction of 
anaesthesia, laryngoscopy, tracheal intubation and surgical stimulation 
often evoke cardiovascular responses characterised by alteration in 
systemic arterial blood pressure, heart rate and cardiac rhythm1. The 
response following laryngoscopy and intubation peaks at 1.2 minutes and 
return to baseline within 5 to 10 minutes. 
 
       Though the sympathoadrenal responses are probably of little 
consequence in healthy patients, it is hazardous to those patients with 
hypertension, coronary heart disease, cerebrovascular disease, intracranial 
pathology and hyperactive airways. In such cases, reflex circulatory 
responses such as an increase in heart rate, systemic arterial pressure and 
disturbances in cardiac rhythm need to be suppressed. 
 
       Prof. King et al1., (1951) documented myocardial ischemic changes 
due to reflex sympathoadrenal responses immediately following 
laryngoscopy and intubation with a mean increase in systolic pressure of 
40mmHg even in normotensive individuals. 
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       Pyrs Roberts et al2., (1971) showed exaggerated form of this 
response in hypertensive patients. 
 
       Various systemic as well as topical agents have been used to reduce 
these untoward hemodynamic responses during laryngoscopy. When 
compared to systemic agents, administration of  local anaesthetic 
solutions are likely to be of limited value. The commonest strategies 
adopted are narcotics, vasodilators, β-blockers, calcium channel blockers, 
lignocaine, clonidine and other sympatholytics. In our study, we have 
compared lignocaine, clonidine, esmolol and placebo in suppressing 
stress responses to laryngoscopy and intubation. 
 
       Since clonidine, lignocaine3 and esmolol have been known to blunt 
sympathetic responses to intubation , their efficacy has been compared 
with control (placebo) in the Department of anaesthesiology, MMC 
(GGH), Chennai. 
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AIM OF THE STUDY 
 
 
 
       For the safe conduct of anaesthesia, the hemodynamic responses to 
laryngoscopy and intubation should be abolished or at least attenuated to 
balance the myocardial oxygen supply and demand . This study was done 
to compare the efficacy of intravenous clonidine, esmolol, lignocaine and 
placebo in attenuating the hemodynamic stress responses to laryngoscopy 
and intubation. 
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PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL 
RESPONSES TO DIRECT LARYNGOSCOPY AND 
INTUBATION. 
        
          Intubation of the trachea alters respiratory and cardiovascular 
physiology by both reflex response and by the physical presence of the 
endotracheal tube. Although the reflex responses are generally of short 
duration and of little consequence in the majority of patients, they may 
produce profound disturbances in patients with underlying abnormalities 
such as hypertension, coronary artery disease, reactive airways and 
intracranial pathology. 
 
Cardiovascular responses: 
       The   cardiovascular  responses  to  laryngoscopy  and  intubation  are 
bradycardia,tachycardia, hypertension and they are mediated by both the 
sympathetic and parasympathetic nervous systems. Bradycardia is often 
seen in infants and small children during laryngoscopy and intubation. 
Although rarely seen in adults, this reflex is mediated by a rise in vagal 
tone at the sinoatrial node and is virtually a monosynaptic response to a 
noxious stimulus to the airway. 
       The more common response to endotracheal intubation is 
hypertension and tachycardia mediated by sympathetic efferents via the 
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cardioaccelerator fibres and sympathetic chain ganglia. The polysynaptic 
nature of pathways from the 9th and 10th nerve afferents to the 
sympathetic nervous system in the brain stem and spinal cord results in a 
diffuse autonomic response which includes widespread release of 
norepinephrine from the adrenergic nerve terminals and adrenal medulla. 
 
       Some of the hypertensive responses to endotracheal intubation also 
results from activation of renin- angiotensin system with release of renin 
from the renal juxta glomerular apparatus and endorgan innervated by β-
adrenergic nerve terminals. 
 
       The effects of endotracheal intubation on the pulmonary vasculature 
are probably less well understood than the responses elicited in the 
systemic circulation. They are often coupled with changes in airway 
reactivity associated with endotracheal intubation. They are: 
 
1. reflex glottic closure , i.e. laryngospasm due to brisk motor 
response 
2.  reduction in dead space 
3. increase in airway resistance 
4. bronchospasm as a reflex response to intubation 
5. cough efficiency is reduced. 
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 METHODS TO ATTENUATE CIRCULATORY 
RESPONSES DURING LARYNGOSCOPY AND 
INTUBATION. 
 
        The balance of myocardial oxygen supply and demand must be 
preserved to minimise the risk of perioperative myocardial ischemia and 
infarction. 
 
Factors affecting myocardial oxygen supply and demand 
        Supply: 
1. heart rate – diastolic time depends upon heart rate. Hence 
slower the heart rate, more the diastolic time and more the 
oxygen supply to the myocardium. 
2. coronary perfusion pressure – depends on aortic diastolic 
pressure and left ventricular end diastolic pressure, it increases 
with a high aortic diastolic pressure and a low end diastolic 
pressure. 
3. arterial oxygen content – depends upon arterial oxygen 
tension and haemoglobin concentration. 
4. coronary vessel diameter.  
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        Demand : 
1. basal requirement 
2. heart rate 
3. wall tension – preload,afterload 
4. contractility. 
         A number of methods were used to attenuate cardiovascular 
response due to laryngoscopy and endotracheal intubation. 
 
1. Deepening of general anaesthesia: 
       Inhalational agents – “MAC-ei” – the dose of volatile agents required 
to block the cardiovascular responses to endotracheal intubation. This 
deep level of anaesthesia achieved by inhalational agents result in 
profound cardiovascular depression prior to endotracheal intubation. 
Various agents used are halothane, isoflurane and sevoflurane. 
 
2. Lignocaine : 
a. lignocaine gargle for oropharyngeal anaesthesia. 
b. aerosol for intratracheal anaesthesia 
c. topical spray over vocal cords 
d. regional nerve blocks – superior laryngeal nerve and      
    glossopharyngeal nerve. 
e. intravenous bolus for systemic anaesthesia. 
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Topical anaesthesia of upper airway has been proven to be less effective 
than systemic administration of lidocaine. 
 
Mechanism :  
1. by increasing the depth of anaesthesia. 
2. potentiation of effects of N2O anaesthesia and reduction of 
MAC  of volatile agents. 
3. direct cardiac depression 
4. peripheral vasodilatation 
5. antiarrythmic properties 
6. suppressed cough reflex. 
 
3. Clonidine: 
        It is an alpha 2 receptor agonist. Clonidine 4 to 5 mcg/kg orally 60 to 
120 minutes prior to intubation or 1 to 3 mcg/kg intravenously 
immediately prior to intubation attenuates hemodynamic responses. 
Mechanism of action of alpha 2 agonist is by decreasing central 
sympathetic outflow, increasing the parasympathetic tone and by 
decreasing circulating nor adrenaline concentration. 
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4. Intravenous vasodilators: 
  
Hydralazine 
Sodium nitroprusside 
Nitroglycerin 
 
5. Narcotics: 
 
Fentanly                Morphine 
Alfentanyl              Pethidine   
Sufentanyl             Nalbhuphine 
 
       Fentanyl is the most commonly used narcotic agent. It is a potent 
analgesic, has a short duration of action, does not increase intracranial 
tension and has minimal circulatory changes. 
 
6. Adrenergic blockers: 
 
Long acting : metoprolol, phentolamine, propranolol, labetalol 
Short acting: esmolol  
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       Of these, esmolol is the most commonly used agent because of its 
ultrashort action. 
       It reduces heart rate, systolic blood pressure, ejection fraction and 
cardiac index but it maintains coronary perfusion pressure. 
 
7. Calcium channel blockers: 
       Nifedipine, nicardipine, verapamil, diltiazem17. 
Of these agents, nicardipine has got superior action. 
 
8.Sedatives and anxiolytics:  
       Midazolam and magnesium sulphate. 
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PHARMACOLOGY OF CLONIDINE 
 
       Clonidine is a prototype, partially selective alpha-2 agonist (α 2: α1 = 
220:1). It is a centrally acting imidazole compound. It was synthesised in 
the early 1960s as a vasoconstricting nasal decongestant. 
 
Structural formula: 
 
 
 
       Its molecular formula is (2-(2,6- dichlorophenyl amino)-2-
imidazoline) and has a molecular weight of 266.56. Available as             
a) 0.1mg, 0.15mg, 0.2mg, 0.3mg tablets 
b) injection (parenteral) – 0.15mg/ml ampuole. 
c) preservative free injection( for epidural injection) – 0.1mg/ml ampuole 
d) transdermal therapeutic patch- 0.1mg/24 hrs or 0.2mg/24 hrs or 
0.3mg/24hrs 
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Pharmacokinetics: 
       Oral clonidine is well absorbed with bioavailability of nearly 
100%26.Intravenously administered clonidine has a bioavailability of 
100% and has a peak effect of action between 60 to 120 minutes and its 
action lasts for upto 8 hours. Clonidine has a low to moderate protein 
binding capacity (20 to 40%), mean elimintation half life of about 12 
hours which is increased upto 40 hours in patients with renal dysfunction. 
Nearly 50% is eliminated unchanged in urine and remaining drug 
undergoes hepatic biotransformation. Biliary and fecal excretion is 
responsible for 20% of drug elimination. 
 
Pharmacodynamics: 
       Clonidine acts on various systems in the body. 
 
Cardiovascular system: Clonidine has both central and peripheral 
action.   
Central: Activation of central α -2 adrenergic receptors in the medullary 
vasomotor centre inhibits the release of norepinephrine from the 
adrenergic neurons and reduces the sympathetic outflow from the central 
nervous system. Further, there is reduced discharge from the 
postganglionic fibres of cardiac nerves and an increase in 
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parasympathetic tone. This results in decrease in blood pressure, heart 
rate, cardiac output and peripheral venous resistance. 
 
       Nucleus tractus solitarious, the site that modulates the autonomic 
control including vagal activity is a important central site for the action of 
clonidine. Decrease in the sympathetic tone is accompanied by lowering 
of plasma renin activity, decrease in renal vascular resistance and 
maintenance of renal blood flow even when the blood pressure is 
lowered. Vasopressor centres of the brainstem retain their sensitivity to 
baroreceptor control and hence postural hypotension is considerably less 
than the effect of drugs that act on autonomic ganglia and peripheral 
adrenergic neurons. 
 
Peripheral action: These are  mediated by inhibition of norepinephrine 
release from the peripheral prejunctional nerve endings and by decreasing 
plasma concentration of norepinephrine. 
 
Coronary circulation: The direct effect of α -2 agonists on coronary 
vasculature is vasoconstriction. However, this is offset by the generalised 
reduction in sympathetic outflow. 
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Central nervous system: Clonidine has sedative and anxiolytic actions. 
The sedative effect of clonidine may be due to decreased tonic activity of 
the locus coeruleus which modulates the stimuli arriving in the central 
nervous system. Clonidine has an opioid sparing effect and it reduces the 
anaesthetic requirements. It reduces the MAC value of halothane and 
isoflurane. It suppresses physiological and psychological symptoms after 
withdrawal of opioid, alcohol, benzodiazepines, barbiturates, nicotine 
etc., in addicted patients. 
 
Respiratory system: It has minimal bronchodilating and respiratory 
depressant activity. 
 
Endocrine system: Clonidine suppresses insulin secretion, decreases 
utilization of glucose by tissues and may cause hyperglycemia. It inhibits 
the secretion of renin. 
 
Gastrointestinal system: It decreases salivary flow. It prevents intestinal 
ion and water secretion in the large bowel. 
 
Uses:  
       It is used as a pre-anaesthetic medicant through oral or intravenous 
route and it provides sedation, anxiolysis, antisialagogue effect, decreases 
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doses of anaesthetic drugs, attenuates the hemodynamic responses to 
laryngoscopy and intubation, decreases intraoperative lability of blood 
pressure and heart rate, decreases MAC of volatile agents, provides 
analgesia and reduces post-operative shivering. Thus preservative free 
clonidine when injected epidurally (2-10mcg/kg) or in to the sub-
arachnoid space (0.3 to 3 mcg/kg) produces dose dependent analgesia and 
prolongation of regional anaesthesia by acting on the substantia 
gelatinosa of spinal cord. Injection clonidine 3 mcg/kg administered 
intravenously inhibits shivering by inhibition of central thermoregulatory 
control. Oral clonidine attenuates the heart rate and blood pressure that 
usually follows ketamine administration. It is also used to diagnose 
phaeochromocytoma where there is lack of suppression of plasma 
norepinephrine to less than 500 pg/ml, three hours after a oral dose of 
0.3mg clonidine. It is also used in the treatment of hypertension and 
diabetic diarrhoea. 
 
Overdosage: 
        It results in depression of sensorium, transient hypertension followed 
by hypotension and bradycardia. It may cause respiratory depression and 
miosis which resembles the effects of opioid. 
In case of overdosage, ventilatory support and circulatory support with 
crystalloids, colloids, inotropic agents and atropine are needed. 
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Contraindications:  
       Clonidine is contraindicated in patients with sinus node disease and 
atrioventricular node dysfunction. It is to be avoided in patients on 
diuretics, having hemodynamic instability and in pregnant patients. 
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PHARMACOLOGY OF ESMOLOL 
 
 
 
 
 
       Esmolol is a phenoxypropanolamine derivative which is structurally 
related to metoprolol, posses’ ester group at para position of its aromatic 
ring. Such para substitution confers cardioselectivity on esmolol, with the 
ester group accounting for high metabolic lability and therefore duration 
of action. 
 
        Esmolol has minimal partial agonist activity and direct membrane 
depressant activity, but it decreases heart rate, depresses atrioventricular 
node conduction and decreases myocardial oxygen demand. While these 
actions are similar to “general” effect of beta blockers, esmolol has the 
clinical advantage of a short duration of action. 
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Cardioselectivity:  
       Beta blockers are classified according to their selectivity for different 
beta adrenoreceptor subtypes. Basically compounds active on both β-1 
and β-2 receptors are non-selective. Since  β-1 receptors are found mainly 
in the heart, drugs with greater selectivity for β-1 than  β-2 receptor are 
cardioselective.  
 
Electrophysiological effect:  
       Action of esmolol on sinus and atrioventricular node function were 
similar to action of other β-blockers. Significant increase in sinus cycle 
length, sinus node recovery time, intervals during sinus rhythm were 
noted. Intervals during 600ms atrial pacing and cycle length at which 
wenkebach periodically develop were prolonged. 
 
Hemodynamic effects: 
  
       Reduces resting heart rate 
       Decreases systolic blood pressure 
       Left and right ventricular ejection fraction is decreased 
       Decreases cardiac index 
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       These are the hemodynamic properties of esmolol in several studies 
involving patients with coronary artery disease and normal cardiovascular 
functions undergoing larnygoscopy and intubation. 
 
Pharmacokinetics18:  
       Esmolol is rapidly hydrolysed by cytoplasmic esterases in red blood 
cells. It therefore has a short elimination half life of approximately 9 
minutes with wide range of inter subject variability ( range 6 – 15 min). 
Hence intravenous esmolol produces peak hemodynamic effects with in 
6-10 minutes of administration. 
 
       The onset of beta blockade with esmolol shows that esmolol 
produces at least 90% steady state of beta blockade within 5 minutes of 
starting bolus dose. Only small fraction (<1%) of esmolol is excreted in 
urine as unchanged drug. The major fraction of intravenous dose of 
esmolol is detectable in urine as acid metabolites which has longer 
elimination half life ( approximately 4 hrs) and slower clearance rate than 
the parent compound. However, acid metabolites has only weak β-
blocking actions- approximately 1500 times less active than parent 
compound. 
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       Most importantly, esmolol metabolism is not influenced by renal or 
hepatic functions. Drug is rapidly hydrolysed by RBC esterases and is 
rapidly cleared by the body. 
 
Tolerance:  
       Adverse events reported during esmolol therapy include bradycardia, 
hypotension, deterioration of heart failure, rebound ischemia, 
bronchoconstriction and fatigue. 
Esmolol has been rarely associated with serious cardiovascular 
complications like severe hypotension, cardiac arrest in patients with 
compensatory tachycardia secondary to hypovolemia, cardiac failure or 
acute myocardial infarction. 
 
Drug interactions: 
        Although the onset of succinylcholine induced neuromuscular 
blockade was not influenced by esmolol in patients undergoing surgery 
with general anaesthesia, the duration of such blockade was prolonged 
from 5 – 18 minutes. Morphine increases the steady state blood levels of 
esmolol by 46%, but other pharmacokinetic parameters were not altered. 
Esmolol has been found to increase digoxin levels in blood by 10-20% in 
12 healthy volunteers in a study. Steady state esmolol concentrations ere 
equivocally increased during concurrent administration of warfarin and 
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esmolol. Interactions between calcium channel blockers and esmolol 
exists and it is recommended that esmolol be used with caution in patients 
with left ventricular dysfunction who are receiving verapamil. Esmolol 
and verapamil should not be administered concomitantly in patients with 
conduction abnormalities and esmolol should not be given with in 48 
hours of stopping verapamil treatment. 
Catecholamine depleting drugs (e.g reserpine) may have additive effect 
when administered along with beta blockers. Thus patients receiving 
concurrent therapy of esmolol and catecholamine depleters, should be 
closely monitored for signs of bradycardia and hypotension which may 
lead to syncope, vertigo and postural hypotension. 
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PHARMACOLOGY OF LIGNOCAINE 
 
 
       Lignocaine is an amide local anaesthetic with antiarrhythmic 
properties. Lofgren first noticed that all local anaesthetics have a 
hydrophilic portion (secondary or tertiary amine) and a lipophilic portion 
(aromatic residue) separated by an intermediate chain. Linkage to the 
aromatic residue has provided a means for classification of local 
anaesthetics. Local anaesthetics with an ester linkage between the 
aromatic residue and intermediate chain are AMINOESTERS (procaine, 
chlorprocaine and tetracaine) and those with an amide linkage between 
the aromatic residue and intermediate chain are AMINOAMIDES 
(lignocaine, bupivacaine, mepivacaine etc,) 
 
       It belongs to class 1b of the Vaughan Williams classification of 
antiarrhythmic drugs. Lignocaine blocks the fast sodium channels in the 
cell membranes of myocardial cells and reduces the rate of rise of the 
action potential in the His purkinje system and the ventricular 
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musculature. The duration of the action potential and effective refractory 
period are reduced. The sinoatrial node and atrio-ventricular node are not 
affected by therapeutic concentrations of lignocaine. 
 
Pharmacokinetics : 
       The pharmacokinetics of lignocaine is well described by a two 
compartment model following a single intravenous dose. Its distribution 
half life (t ½α) is around 8 minutes and its elimination half life (t½β) is 
around 90 to 110 minutes. Lignocaine is metabolised in the liver to 
monoethylglycinexylidine (MEGX) and glycinexylidine (GX) which are 
then excreted by the kidney. As lignocaine is rapidly cleared by the liver 
its plasma steady state concentration depends on the hepatic blood flow. 
Thus in conditions where hepatic blood flow is reduced as in congestive 
cardiac failure or in the presence of hepatic disease the dosage of 
lignocaine should be reduced. Lignocaine has a molecular weight of 234. 
Its protein binding is between 60-75% . Therapeutic plasma 
concentrations required to produce an antiarrhythmic effect is around 
1.5µg/ml. Convulsions occurs at a plasma concentration of around 
10µg/ml. 
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Indications: 
1. Intravenous lignocaine is the drug of choice for management of 
ventricular arrhythmias like ventricular premature contractions. 
2. Intravenous lignocaine is used during anaesthesia to prevent the 
pressor response to laryngoscopy and intubation. 
3. Lignocaine is used as a local anesthetic for topical infiltration and 
other regional anaesthetic procedures. 
 
          It is available as 1%, 2%, 4%, and 10% solutions. A 5% solution 
with 7.5% dextrose is available for subarachnoid block. The preparations 
for intravenous use do not contain preservatives. Usual dose for 
intravenous administration is 1- 1.5mg/kg body weight followed by an 
infusion at a rate of 1-4 mg/min if required. For infiltration lignocaine can 
be used up to a maximum dose of 3 mg/kg body weight without 
adrenaline and 7mg/kg body weight with adrenaline. 
 
Contraindications: 
1. Hypersensitivity to lignocaine. 
2. Hypersensitivity to other amide local anaesthetics (which is rare). 
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Precautions: 
1. Patients with hepatic or renal dysfunction: 
      Lignocaine is mainly metabolised in the liver and the metabolites are 
excreted by the kidney. Caution should be observed while administering 
lignocaine to patients with these disorders especially as infusion as it may 
lead on to an accumulation of metabolites potentially toxicity. 
        2. When high doses are used in patients with impaired myocardial 
function it can potentiate the negative inotropic effect and cause clinical 
hypotension. 
       3. Serum potassium levels should be normalised prior to starting an 
infusion of lignocaine.       
 
Toxicity: 
       Toxicity of local anaesthetics chiefly involves the central nervous 
system and cardiovascular system. The earliest symptom in an awake 
patient include circumoral paraesthesias and numbness, which then 
proceeds onto tinnitus, nystagmus and dizziness. Further increase in 
plasma concentration can lead onto CNS excitation restlessness and 
tremors leading onto convulsions. At toxic doses the combined effects of 
peripheral vasodilation, negative inotropic effect and a depressant action 
on cardiac conduction can lead onto circulatory collapse and cardiac 
arrest. 
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      The ratio of the dosage or blood levels required to produce 
irreversible cardiovascular collapse to the dosage or blood levels required 
to elicit convulsions is the CC/CNS ratio. The CC/CNS ratio for 
lignocaine in adult non-pregnant sheep is 7 indicating that 7 times as 
much drug is needed to produce irreversible cardiovascular collapse as is 
required to produce convulsions. Hence central nervous system 
symptoms provide a warning in an awake patient of high plasma levels 
and impending cardiovascular collapse. 
 
Management of toxicity: 
1. Administer 100% oxygen , intubate if necessary. 
2. seizures are managed by intravenous benzodiazepines or 
thiopentone sodium. 
3. Cardiovascular depression is managed by intravenous fluid 
administration and vasopressors. Prolonged inotropic support may 
be required. 
4. Hypoxia and acidosis worsen cardiovascular collapse and should 
be aggressively managed. 
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REVIEW OF LITERATURE 
 
       The hemodynamic consequences of endotracheal intubation have 
been the subject of study by various authors over many years. 
 
       Ried and Brace (1940) postulated that the reflex circulating responses 
to laryngoscopy and intubation were mediated through vagus nerve and 
named it as “VASOVAGAL REFLEXES” 
 
       King et al.,( 1951) observed that a marked, through a transient rise in 
blood pressure which is often encountered during laryngoscopy and 
manipulation of the epiglottis. They stated that the impulses initiating the 
reflex are probably carried by the vagus nerve while the effector system is 
less clearly defined and may be due to decreased parasympathetic or 
increased sympathetic activity. 
 
       Prof.Ward and King (1960) in their study documented myocardial 
ischemic changes due to reflex sympathoadrenal responses following 
laryngoscopy and intubation with mean increase in systemic pressure of 
40mmHg even in normotensive individuals. 
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       SeinhansGanskins (1963) found that intravenous lidocaine 
suppressed the cough reflex, rise in blood pressure, rise in heart rate and 
intracranial pressure. 
 
       Masson & Eckanoff (1971) found the increase in heart rate and blood 
pressure are much more exaggerated in hypertensive patients which can 
be significantly decreased by simple lidocaine spray. 
  
       Pyrs – Roberts et al., (1971) found the increase in heart rate and 
blood pressure are much exaggerated in hypertensive patients. 
 
       Robert K. Stoelting et al4., (1977) studied about the influence of 
duration of laryngoscopy with or without lidocaine and found that blood 
pressure response was attenuated but not prevented by either 
oropharyngeal topical or intravenous administration of lidocaine and 
attempts to attenuate the response would seem to be most appropriate 
when intubation is likely to take more than 30 seconds. 
 
       Robert K. Stoelting et al5., (1978) in his study concluded that a short 
duration of direct laryngoscopy combined with laryngotracheal lidocaine 
administered just before intubation minimises pressor responses. 
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       Robert K. Stoelting et al., (1978) demonstrated that bolus dose of 
sodium nitroprusside (1-2 mcg/kg) injected just before administration of 
induction agents was successful in attenuating the responses to 
endotracheal intubation. 
 
       Batra YK, Indu B, Puri GD6 (1988) studied the attenuation of pulse 
rate and blood pressure responses to laryngoscopy and intubation by oral 
clonidine and concluded that oral clonidine does circumvent the response. 
 
       Inadae, Cullen DJ Nemeskar AR (1989)7 compared the efficacy of 
lidocaine 2mg/kg, labetolol 10mg intravenous injection just prior to 
induction of anaesthesia and found lidocaine is a safe and cost effective 
mean of preventing tachycardia but not hypertension in response to 
laryngoscopy and intubation. 
 
       Ebert TJ Beenstien JS (1990)8 studied the hemodynamic responses to 
rapid sequence induction and intubation in healthy patients with a single 
bolus dose of esmolol. They concluded that esmolol 2 mg/kg bolus 
effectively attenuated heart rate, systolic blood pressure and rate pressure 
product increase produced by intubation. 
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       Sheppard S et al., (1990)10 compared different bolus doses of esmolol 
and concluded that the attenuation of intubation responses is adequate 
following 100mg of esmolol. 
 
       Ghignone et al21., (1987) observed that clonidine 5 mcg/kg 
administered to patients with controlled hypertension was more effective 
in blunting the reflex tachycardia associated with laryngoscopy and 
intubation then lidocaine – fentanyl pretreatment. 
 
       Pouttu et al25., (1987) evaluated the effect of clonidine (4.5 mcg/kg) 
on stress responses during general anaesthesia in 21 female patients 
undergoing breast surgeries. They observed that clonidine attenuated the 
sympathoadrenal responses and the increase in heart rate and arterial 
blood pressure were lowered in that group. 
 
       Ghignone et al.,(1988) further studied on clonidine on intraocular 
pressure in elderly patients undergoing ophthalmic surgery. They 
observed in addition to attenuation of sympathetic responses to 
laryngoscopy and intubation, rise in intraocular pressure was prevented. 
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       Nishikawa et al22., (1991) studied the premedication with oral 
clonidine in a dose of 5 mc/kg and observed that it could attenuate the 
pressor responses associated with laryngoscopy and intubation. 
 
       Helfman SM et al16., (1991) compared lidocaine, esmolol, fentanyl in 
attenuation of hemodynamic responses to laryngoscopy and intubation. 
Similar study was done by Feng et al., (1996). In both the studies, they 
have concluded that esmolol, offered a consistent and reliable protection 
in attenuating tachycardia and hypertension associated with intubation. 
 
       Vucevic M et al11., (1992) studied about the line of esmolol for 
management of cardiovascular stress responses to laryngoscopy and 
intubation and found that pressor responses to laryngoscopy was 
significantly less marked in patients given esmolol 2 minutes before 
intubation. 
 
       Chadha et al.,(1992) evaluated oral clonidine pretreatment for 
hemodynamic stability during craniotomy. They observed that pressor 
responses to laryngoscopy, intubation and skin infiltration was 
significantly attenuated in the clonidine group. 
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       Ching KS et al., (1992) studied on comparison of fentanyl, esmolol 
and their combination for blunting the hemodynamic responses during 
rapid sequence intubation and they concluded that a combination of low 
dose fentanyl and esmolol provides an alternative to high dose fentanyl 
for blunting the hemodynamic responses to laryngoscopy and intubation. 
 
       Yuan L, chia YY ( 1994) studied the efficacy of bolus dose of 
esmolol in blunting the stress responses to intubation, comparing 100mg 
esmolos vs 200mg esmolol. They concluded that both bolus doses could 
effectively attenuate the tachycardia and hypertension produced by 
laryngoscopy and intubation. Further, esmolol 100mg presents a better 
hemodynamic stability than esmolol 200 mg during induction of 
anaesthesia. 
 
       Dorman et al., (1993) observed that clonidine 5 mcg/kg improves 
perioperative myocardial ischemia in patients undergoing CABG. Yin et 
al., (2002) observed the same results in CAD patients undergoing non-
cardiac surgery. 
 
       Stuhmeier et al., (1996) studied the effect of small dose of clonidine 
(2mcg/kg) in patients undergoing vascular surgery and observed that it 
reduces the incidence of myocardial ischemia. 
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       Thomson et al., (1998) compared clonidine with conventional pre-
anaesthetic medication ( morphine with scopolamine or lorazepam) in 
patients undergoing CABG and observed that clonidine produces 
sedation, relieves anxiety as effective as conventional premedicant. They 
also observed that clonidine significantly reduces the isoflurane 
requirements. 
 
       Tetsu kimura et al., (1998) observed that premedicant with oral 
clonidine (5 mcg/kg) attenuated the initial increase in heart rate without 
subsequent decrease in heart rate after intravenous neostigmine and 
atropine administration. 
 
       Groundman et al., (1997) observed that intraoperative administration 
of 2 mcg/kg of intravenous clonidine is suitable for prevention of 
postanaesthetic shivering without prolonging the recovery time. 
 
       Michael A Campagni et al., (1999) evaluated oral clondine and 
intravenous esmolol regarding hemodynamic changes associated with 
injection of epinephrine containing local anaethetic drug during 
endoscopic sinus surgery on septoplasty surgery in young healthy non 
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smokers. They observed that tablet clonidine 0.2 to 0.4 mg was efficient 
in blunting the hemodynamic responses. 
 
       Laurito et al., (1991)24 concluded that oral clonidine 0.2 mg was 
effective in blunting systemic hypertension produced by prolonged 
laryngoscopy. 
 
       Bensky KP et al., (2000) in their study concluded that small doses of 
esmolol may block the rise in heart rate and blood pressure resulting from 
laryngoscopy and intubation. 
 
       Eva Oddby-Muhrbeck et al., (2002) observed that co-induction with 
clonidine significantly increased the number of PONV free patients after 
breast surgery with general anaesthesia. 
 
       Singh H 31et al., (1995) in their study concluded that lidocaine 1.5 
mg/kg intravenously and nitroglycerin 2 mcg/kg intravenously were 
ineffective in controlling the acute hemodynamic responses following 
laryngoscopy and intubation. Esmolol 1.4 mg/kg intravenously was more 
effective than either lidocaine or nitroglycerin in controlling stress 
responses. 
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       Miller DR et al., (1991) in their Canadian multicenter trail involving 
five hundred and forty eight patients concluded that 100mg bolus of 
esmolol is a safe and effective agent. This dose of esmolol combined with 
a low dose of narcotic ( fentanyl 2 mcg/kg) results in effective control of 
both heart rate and blood pressure, while avoiding important side effects. 
 
       Dipak L Raval et al35., (2002) compared oral clonidine and oral 
diazepam and concluded that clonidine was more effective in blunting 
sympathoadrenal responses. 
 
       Zulandaro et al34., (2001) compared intravenous clonidine 3mcg/kg 
with intravenous esmolol 2mg/kg in randomly allocated 44 patients ( 22 
in each group) and concluded that clonidine is effective in attenuating 
sympathoadrenal responses to intubation than esmolol with statistical 
significance, p value being less than 0.05. 
 
       Carabine et al23., (1991) compared two doses of intravenous 
clonidine ( 0.625 mcg/kg and 1.25 mcg/kg) in attenuating intubation 
responses and observed that both the doses equally and effectively 
blunted the pressor responses to laryngoscopy and intubation. 
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MATERIALS AND METHODS 
 
       One hundred and twenty patients of ASA physical status 1 or 2 
undergoing elective surgical procedure under general anaesthesia with 
endotracheal intubation were included in this study. 
 
       Patients belonging to age group 15 to 60 years of both the sexes were 
included. It is a prospective randomized controlled study. The study was 
approved by our institution ethical committee and after obtaining written, 
informed consent from the patient, this study was conducted. 
 
       The study was done during the period from June 2009 to august 2009 
in the Department of Anaesthesiology, Govt. General hospital, Chennai 3. 
 
Inclusion criteria: 
1) ASA 1 or 2 
2) Patients with airway with modified mallampatti grade class 1 or 2 
3) Age group 15 to 60 years of both sexes.                                                                       
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Exclusion criteria: 
1) Patients with full stomach 
2) Patients posted for emergency surgery 
3) Patients with difficult airway 
4) Hypertension, diabetes, ischemic heart disease and pregnancy 
5) Patients with contraindications to study drugs. 
6) Patient refusal 
 
Materials: 
1)   Injection thiopentone 2.5% solution 
2)   Injection suxamethonium 
3)   Injection glycopyrollate 
4)   Injection fentanyl 
5)   Injection esmolol hydrochloride( esocard) 100mg/10ml vial 
6)   Injection ligocaine 2% (preservative free) 
7)   Injection clonidine 0.15mg/ml ampoule 
8)   Normal saline 
9)   Disposable 10 ml syringe 
10)  Larynyngoscope with blades 3 and 4 
11)  Endotracheal tubes of various sizes. 
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Pre anaesthetic preparations: 
        All the patients were admitted and they underwent routine 
investigations like: 
 
Hemogram 
Blood urea and sugar 
Serum creatinine and electrolytes 
Chest x ray 
Electrocardiogram 
 
Other investigations were obtained on the basis of the condition of the 
patient. 
 
Anaesthetic protocol: 
       Pre-operative visit was done to allay anxiety and good rapport was 
established with the patients. All the patients were given pre-operative 
night sedation with tab.diazepam 10mg orally. 
 
Interventions: 
       Induction of anasesthesia was standardised for all patients. Monitors 
used were NIBP, ECG, Et co2 and pulse oximetry. 
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Method: 
       One hundred and twenty patients of both the sexes of ASA 1 or 2 
undergoing surgical procedure were randomly allocated into four groups. 
 
       Group C ( clonidine 2 mcg/kg) – 30 patients were given intravenous 
clonidine 2 mcg/kg 2 minutes before induction. 
 
       Group E (esmolol 1mg/kg)  -- 30 patients were given intravenous 
clonidine 1 mg/kg 2 minutes before induction. 
 
       Group L (lignocaine 1.5mg/kg) – 30 patients were given intravenous 
lignocaine 1.5mg/kg 2 minutes before induction 
 
       Group P ( placebo- normal saline) –30 patients were given normal 
saline 2 minutes before induction. 
 
Premedication: 
       Patients are shifted to the operating table. Their pulse rate, blood 
pressure and sp02 were recorded. They were premedicated with injection 
glycopyrollate 4 mcg/kg body weight intravenously and injection fentanyl 
2mcg/kg body weight intravenously. Then, their heart rate, blood pressure 
and sp02 were recorded. 
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Preoxygenation: 
       It is done with 100% oxygen for 3 minutes. 
 
Administration of study drug: 
       The study drug was taken in a 10 ml syringe in a diluted form and 
given in bolus over 10 to 15 seconds. Then vital signs were recorded. 
Two minutes later, patient was induced with injection thiopentone 2.5%  
5mg/kg body weight intravenously. Then, injection succinycholine 
1.5mg/kg body weight was given. Intubation was performed by the same 
person for all the cases with appropriate sized endotracheal tubes 
orotrachealy. 
 
        Anaesthesia was maintained with controlled ventilation with 
N2O/O2 mixture 2:1 and injection atracurium 0.5mg/kg given as initial 
dose. No surgical stimulation was permitted for 5 minutes after 
intubation. 
 
       Patients were monitored throughout the period from entering into 
operation theatre till recovery and in the immediate post operative period 
by means of automated NIBP, pulse oximetry and ECG in a multichannel 
monitor. ECG was monitored with particular importance to any alteration 
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in rhythm. All patients were extubated and were shifted to post 
anaesthetic care unit for a follow up for  24 hours. Results were tabulated 
and analysis done by ‘t’ test. A  p – value of less than 0.05 was 
considered as statistically significant. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
 
OBSERVATION AND RESULTS 
 
 
          One hundred and twenty patients under this study were categorised 
into four groups. 30 in each group. They compromised both sexes in the 
age group 15 to 60 years. The demographic profile is as follows: 
 
 
Characteristics Group-C Group-E Group-L Group-P 
Age ( yrs) 
 
26.03±7.10 
 
26.67±7.87 24.97±7.90 27.90±6.30 
Sex 
 
 
M-15 
F-15 
M-14 
F-16 
M-17 
F-13 
M-13 
F-17 
 
Weight(kgs) 
 
49.40±7.16 
 
52.37±8.05 50.77±6.79 52.77±7.12 
Basal heart rate 
 
90.67±16.68 97.20±14.85 89.23±15.88 87.60±7.99 
 
Basal systolic 
blood 
pressure(mmHg) 
 
124.00±9.45 124.80±10.77 120.47±8.04 120.37±8.67
Basal diastolic 
blood 
pressure(mmHg) 
 
83.13±7.66 82.20±6.43 80.40±6.64 78.83±6.79 
Basal mean arterial 
pressure(mmHg) 
 
96.73±7.79 96.47±7.69 93.80±6.47 92.63±6.82 
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Age group ( Years) 
 
GROUP N Mean Standard 
deviation 
F-test 
C 30 26.03 7.10 F=0.8414 
P=0.4739 E 30 26.67 7.87
L 30 24.97 7.90 
P 30 27.90 6.30 
 
       In the group C, the mean age was 26.03±7.10 years, ranging from 16 
to 41. In the group E, the mean age was 26.67±7.87 years, the range 
being 16 to 45. In the group L, the mean age was 24.97 ±7.90, the range 
being 16 to 48, and in the group P, it was 27.90±6.30, the range being 18 
to 46. Thus, there is no significant difference between the four groups as 
their p=0.4739 ( p value of significance being < 0.05) 
 
Sex distribution 
 
Sex Group C Group E Group L Group P Total 
Male 15 14 17 13 59 
Female 15 16 13 17 61 
Total 30 30 30 30 120 
 
p = 0.7609 ( p value of significance being < 0.05) 
 
The sex difference between the four groups is equal as shown in the bar 
chart, the difference being insignificant ( p = 0.7609) 
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Weight distribution (kgs) 
 
 
Group  N  Mean (kgs) Standard deviation f-test  
C 30 49.40 7.16 F=0.07 
p = 0.93 E 30 52.37 8.05
L 30 50.07 6.79 
P 30 52.77 6.10 
 
In the group C, the mean weight was 49.40±7.16 ranging from 35 to 65 
kg. In the group E, the mean weight was 52.37±8.05 ranging from 42 to 
73 kg. In the group L, the mean weight was 50.07±6.79 ranging from 40 
to 70 kg. In the group P, the mean weight was 52.77±6.10 ranging from 
44 to 70 kg. Thus there was no significant difference between the four 
groups as their p value = 0.93 
 
Baseline Hemodynamic Parameters 
       There was no statistically significant difference in the baseline 
hemodynamic parameters between the four groups. 
 
Basal Heart rate (beats/min) 
 
Group  N  Mean Standard deviation f- test 
C 30 90.67 16.68 F=2.607 
P =0.055 E 30 97.20 14.85 
L 30 89.23 15.88 
P 30 87.60 7.99
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Basal systolic pressure ( in mmHg) 
 
Group  N  Mean  Standard deviation f- test 
C 30 124.00 9.45 F=1.877 
P =0.137 E 30 124.80 10.77 
L 30 120.47 8.04 
P 30 120.37 8.67
 
 
Basal diastolic pressure ( in mmHg) 
 
Group N  Mean Standard deviation f-test 
C 30 83.13 7.66 F= 2.306 
p= 0.080 E 30 82.20 6.43 
L 30 80.40 6.64 
P 30 78.83 6.79 
 
 
Basal mean arterial pressure (in mmHg) 
 
Group  N  Mean Standard deviation f-test 
C 30 96.73 7.79 F= 2.337 
p =0.077 
 
E 30 96.47 7.69
L 30 93.80 6.47 
P 30 92.63 6.82 
 
 
 
46 
 
 
 
 
 
 
 
 
 
HEART RATE CHANGES  ( beats / min) 
 
 
Group  C 
 
E L P 
Base line 90.67±16.68
 
97.20±14.85 89.23±15.88 87.60±7.99 
After 
premedication 
86.90±11.67
 
 
96.97±12.87 92.80±10.76 83.96±9.22 
After study drug 82.37±9.90 
 
 
85.13±12.32 96.63±9.76 84.60±11.43 
After induction 88.13±16.97
 
 
87.97±12.25 97.80±13.38 87.53±10.10 
 
At laryngoscopy 
& intubation 
92.80±15.88 98.67±10.40 110.90±12.94 108.57±10.87
1 min 89.83±15.16
 
92.73±9.27 101.87±12.79 99.17±12.06 
3 min 84.73±13.79
 
90.90±10.20 95.87±11.35 93.73±11.99 
5 min 79.70±12.90
 
89.40±10.26 91.03±11.72 89.87±11.50 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
 
 
 
 
SYSTOLIC BLOOD PRESSURE CHANGES  (mmHg) 
 
 
 
 
Group C E L P 
 
Base line 124.00±9.45 
 
 
124.80±10.77 120.47±8.04 120.37±8.67 
After 
premedication 
122.66±8.12 
 
 
123.16±11.14 119.66±9.97 122.10±9.31 
After study 
drug 
123.06±10.13
 
 
120.10±11.97 120.63±8.98 122.10±12.18
After induction 110.77±26.90
 
 
113.53±14.27 113.07±14.14 116.63±12.13
At 
laryngoscopy & 
intubation 
120.27±16.21 129.30±15.06 138.80±16.90 146.33±15.91
1 min 112.60±14.25
 
 
121.40±13.10 125.77±19.01 131.73±14.87
3 min 106.47±14.55
 
 
115.70±9.91 115.17±15.19 123.17±11.41
5 min 101.90±10.63
 
 
114.20±8.83 112.17±13.94 119.50±10.22
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DIASTOLIC PRESSURE CHANGES (mmHg) 
 
 
 
Group  C 
 
E L P 
Base line 83.13±7.66 
 
 
82.20±6.43 80.40±6.64 78.83±6.79 
After 
premedication 
82.13±9.10 
 
 
80.43±11.43 79.77±7.70 80.43±10.26
After study 
drug 
81.73±6.29 
 
 
80.00±12.73 75.30±7.70 81.33±9.69 
After 
induction 
73.73±10.36
 
 
78.07±8.69 78.00±11.62 77.50±8.89 
At 
laryngoscopy 
& intubation 
84.73±13.83 92.00±9.66 100.27±15.50 95.90±11.57
1 min 77.57±11.45
 
 
85.60±7.05 77.80±11.99 81.70±7.99 
3 min 71.53±12.13
 
 
80.67±7.05 77.80±11.99 81.70±7.99 
5 min 68.93±9.78 
 
 
79.07±6.31 77.03±11.64 77.30±7.48 
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MEAN ARTERIAL PRESSURE CHANGES (mmHg) 
 
 
Group  C 
 
E L P 
Base line 96.73±7.79 
 
 
96.47±7.69 93.80±6.47 92.63±6.82 
After 
premedication 
94.73±9.09 
 
 
94.73±8.89 93.66±12.48 94.33±10.70 
After study 
drug 
95.50±12.67
 
 
93.33±9.09 94.03±8.18 95.26±11.17 
After 
induction 
86.93±14.72
 
 
89.97±10.05 89.70±12.14 90.60±8.98 
At 
laryngoscopy 
& intubation 
96.50±14.23 106.0±12.19 113.0±15.71 112.93±11.95
1 min 89.30±12.07
 
 
98.00±13.69 101.1±16.81 101.70±10.03
3 min 83.20±12.62
 
 
92.27±7.79 90.30±12.62 95.53±8.25 
5 min 79.97±9.73 
 
 
90.73±6.67 88.73±11.97 91.40±7.42 
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DISCUSSION 
 
       Laryngoscopy and endotracheal intubation produces hemodynamic 
stress responses  characterized  by  hypertension  and  tachycardia.    This  
neuroendocrine responses can cause a variety of complications in 
patients with cardiac disease due to imbalance of myocardial oxygen 
supply and demand like ischemic changes, ventricular arrythmias and 
cardiac failure. 
 
       This is also hazardous in patients with vascular pathologies due to  
weakening of lining of major arteries in particular cerebral and aortic 
aneurysms. In patients with hydrocephalus or intracranial mass lesions 
the  increase  in  CSF  pressure   may  produce  transient   impairment  of  
cerebral perfusion leading to cerebral ischemia . 
 
       These reflex responses may be diminished or modified locally or 
centrally and attempts have been made to accomplish this with varying 
success by different techniques and agents. No effective drug has been 
found out so far to abolish this response totally. 
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       Many drugs have been reported to have beneficial effects in partially 
attenuating   sympathoadrenal     responses  to   endotracheal   intubation.  
Injection  lidocaine,  esmolol,  fentanyl,  calcium  channel blockers  have  
been extensively studied by many authors. Alpha 2 agonist clonidine, 
though not extensively studied like other drugs, there are many reports 
stating its beneficial effects in attenuation of circulatory responses to 
endotracheal intubation. 
 
       Batra YK, Indu B, Puri GD et al., in 1988  studied the attenuation of  
circualatory responses to laryngoscopy and intubation by oral clonidine 
(5 mcg/kg) and concluded that oral clonidine does circumvent the 
response. This study result added more supports to earlier studies 
conducted by Ghignone et al., and Pouttu et al in 1987. Carabine et al 
compared different doses of intravenous clonidine in attenuating 
intubating responses in 1991. Zalunardo  et al compared intravenous 
clonidine with intravenous esmolol in attenuating intubation responses 
and found out that intravenous clonidine (3 mcg/kg i.v)was statistically 
significant ( p value < 0.05) in attenuating intuabation responses when 
compared to intravenous esmolol (2mg/kg i.v). 
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       Various studies have reported that lignocaine is  effective12 in 
blunting these responses. Recent studies, however, have questioned 
lignocaine's efficacy. In Singh et al's31 , van den Berg et al's32  and 
Kindler et al's33  study IV Lignocaine 1.5 mg/kg was ineffective in 
controlling the acute hemodynamic response following laryngoscopy and 
intubation. In two different studies, it was shown that lignocaine 1.5 and 
2 mg/kg is ineffective in blunting the responses during rapid sequence 
induction. Bachofen  studied blood pressure responses to endotracheal 
intubation with 1.5 mg/kg lignocaine in patients with intracranial vessel 
malformations or brain tumors. In both groups no significant effect of 
lignocaine on the pressure response could be observed. 
 
       In our study , comparison of intravenous clonidine ( 2mcg/kg), 
lidocaine (1.5mg/kg), esmolol ( 1 mg/kg) and placebo was done in 
attenuating  circulatory responses to endotracheal intubation. The data 
was analysed using Microsoft Excel, and SPSS 10.0 for windows. 
Haemodynamic variables were represented by mean ± SD. Statistical 
significance in mean difference was assessed by the use of One way 
analysis of variance. Tukey's HSD was applied to evaluate inter group 
comparisons. A p value of < .05 was considered as statistically 
significant. 
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Heart rate changes 
       The baseline mean heart rate of all the four groups did not have any 
statistically significant differences as their p value was 0.055. At the time 
of induction also there was no significant difference in mean heart rate 
among the four groups( p = 0.080). Once endotracheal intubation was 
performed, there was a rise in heart rate in all four groups, of which the 
rise in heart rate in group C was found to be least when compared to other 
groups. Though the rise in heart rate in group C is lowest, it is statistically 
insignificant when compared to group E ( p value =  0.068). Group C and 
E differed from group L and P with statististical significance ( p value = 
0.001) in tachycardic response to endotracheal intubation. Our study 
results with regard to heart rate matches with Vucevic et al which proved 
efficacy of esmolol and Carabine et al which proved the efficacy of 
clonidine. Inefficiency of lidocaine in attenuating rise in heart rate in our 
study can be explained by comparing it with Singh et al, Van der begh  et 
al and Kindlers et al  all of whom questioned lidocaine’s efficacy. The 
heart rate in group C stayed significantly lower than all other groups even  
at 5 minutes after intubation ( p value = 0.001), but in group E it stayed 
significantly lower than group L and group P till 3 minutes after 
intubation. After this there was no significant difference among group 
E,L and P which can be explained by the short duration of action of 
esmolol. Thus it is inferred that though clonidine and esmolol are equally 
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effective in blunting rise in heart rate immediately following intubation. 
clonidine provides a better hemodynamic stability than esmolol for a 
longer duration following intubation. 
 
Systolic blood pressure changes 
       There was no significant difference in baseline systolic blood 
pressure values ( p = 0.137) among the four groups. Even at induction, 
there was no difference in systolic blood pressure of all the groups  ( p = 
0.650). After intubation, there was a sudden increase in systolic blood 
pressures in all four groups. Group C and group E differed in attenuation 
of pressor response to intubation  from groups L and P with statistical 
significance ( p value 0.001). Group C had aleast rise in systolic blood 
pressure which when compared with group E was statistically significant 
( p vaule 0.007). There was no difference between group L and group P 
(p value 0.231) Even after 5 minutes, group C differed from all other 
groups showing a sustained attenuation of pressor response. At 3 minutes 
and 5 minutes, there were no statistically significant differences in 
systolic blood pressure among groups E,L and P ( p value 0.124). 
Probably due to shorter duration of action group E could not show much 
difference from group L and group P at 3 minutes and 5 minutes interval . 
Attenuation of pressor responses by group E in our study matches with  
studies conducted by Yuan et al, chings et al and helfman et al. The  
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difference between group C and group E matches with study conducted  
by zulandaro MP et al in 2001 which proved clonidine was more effective 
than esmolol in attenuating pressor response to endotracheal intubation. 
 
Diastolic and mean arterial pressure changes 
        There was no significant difference in baseline diastolic blood 
pressure among the four groups ( p = 0.087) and also in baseline mean 
arterial pressure (p = 0.073). During induction of anaesthesia, the groups 
did not show significant difference in diastolic blood pressure or  mean 
arterial pressure. After intubation, there was a sudden increase in diastolic 
and mean arterial pressures in all the four groups. Group C and group E 
differed from groups L and P with statistical significance in rise in 
diastolic blood pressure( p value 0.001)   as well as in rise in mean 
arterial pressure( p value 0.001) . Group C had least rise in diastolic  
blood pressure and mean arterial pressure which when compared with  
group E were statistically significant ( p vaule being 0.006 and 0.009 
respectively). There was no  difference between group L and group P 
both in the diastolic blood pressure  ( p value 0.462)  and mean arterial 
pressure ( p= 0.312). Even after 5minutes, group C differed from all other 
groups showing a sustained  attenuation of pressor response. At 3 minutes 
and 5 minutes, there were  no statistically significant difference in both 
diastolic blood pressure and mean arterial pressure among  groups E,L 
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and P ( p value 0.223 and 0.412 respectively). Again probably due to 
shorter duration of  action, group E did not show much difference from 
group L and group  P at 3 minutes and 5 minutes interval.  Attenuation of 
pressor responses  by group E in our study matches with  studies 
conducted by Yuan et al, Chings et al and Helfman et al. The  difference 
between group C and group E matches with study conducted  by 
zulandaro MP et al in 2001 which proved clonidine was more effective 
than esmolol in attenuating pressor response to endotracheal intubation. 
 
       Episodes of perioperative hypertension and tachycardia with its 
consequent ill effects on the vital organs can be a significant problem in 
some patients despite adequate depth of anaesthesia and analgesia. This 
study shows the effectiveness of clonidine in attenuating the increase in 
heart rate and blood pressure following endotracheal intubation , thereby 
minimising significantly the imbalance between myocardial demand and 
supply following endotracheal intubation. Clonidine is followed by 
esmolol which attenuates rise in heart rate to intubation as effective as 
clonidine, but not as effective as clonidine in attenuating rise in blood 
pressure to intubation. 
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SUMMARY 
 
This prospective randomised study was designed to evaluate the efficacy 
of intravenous clonidine, esmolol, lidocaine and placebo in suppressing 
the hemodynamic changes during endotracheal intubation. A total of one 
hundred and twenty patients belonging to ASA 1 and 2 were randomly 
divided into four groups. Patients in group C received clonidine 2 
mcg/kg, in group E received esmolol 1 mg/kg, in group L received 
lidocaine 1.5 mg/kg and in group P received normal saline  two minutes 
prior to induction. 
 
The following observations were made: 
1. Patients in group C showed the maximum attenuation of both heart 
rate and blood pressure following endotracheal intubation. 
2. Patients in group E showed a significant attenuation of heart rate                          
as effective as group C but attenuation of blood pressure ( though 
effective than groups L and P) was not as effective as group C. 
3. Patients in group L showed no significant difference from group P in 
attenuating circulatory responses and both lignocaine and placebo were 
ineffective. 
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4. All the patients were recovered well from anaesthesia and none of  
them developed complications like severe bradycardia( HR< 50/min) or 
profound hypotension( SBP < 80 mmHg). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
CONCLUSION 
 
       From the above study it is concluded that the hemodynamic changes 
associated with endotracheal intubation can be safely and effectively 
obtunded by  using intravenous clonidine prior to induction of 
anaesthesia. 
         Clonidine is found to be effective in blunting hemodynamic 
responses to laryngoscopy and intubation, followed by esmolol. 
        Lignocaine and placebo were ineffective in attenuating these 
responses to laryngoscopy and endotracheal intubation.  
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107 88 94 121 137 96 110 114 110 83 92 107 111 78 89 107 110 79 89
122 90 101 125 150 112 125 120 110 79 89 118 109 81 90 124 106 78 87
139 76 97 102 180 112 135 95 160 104 123 80 119 77 91 79 120 82 95
100 69 79 114 134 90 105 108 128 82 97 91 109 74 86 85 105 69 81
130 93 105 110 159 105 123 110 140 82 101 104 136 98 111 94 130 91 104
136 92 107 119 160 120 133 93 133 110 118 90 130 98 109 92 128 82 97
130 86 101 98 159 99 119 86 146 96 113 77 138 86 103 79 132 89 103
114 70 85 84 139 82 101 80 126 76 93 76 118 78 91 75 118 74 89
106 80 89 109 136 96 109 100 120 84 96 96 118 70 86 92 120 64 83
116 80 92 110 154 100 118 106 150 96 114 100 138 86 103 98 136 84 101
138 86 103 102 166 96 119 90 154 90 111 86 140 82 101 77 140 77 98
124 70 88 116 160 90 113 110 150 84 106 108 130 80 97 90 120 76 91
120 80 93 98 152 98 116 82 132 80 97 80 126 74 91 80 120 70 87
124 88 100 118 140 108 119 106 132 102 112 106 128 98 108 98 126 98 107
122 71 88 98 180 100 127 90 160 90 113 86 140 80 100 84 130 76 94
102 63 76 121 156 111 126 107 126 89 101 89 111 75 87 85 110 72 85
108 72 84 108 130 96 107 104 128 94 105 101 128 94 105 99 115 80 92
98 63 75 129 127 74 92 120 118 76 90 118 104 80 88 116 108 70 83
102 72 82 112 150 89 109 100 140 82 101 92 132 88 103 88 136 81 99
139 90 106 94 165 110 128 71 136 96 109 70 130 86 101 69 124 79 94
110 72 85 102 139 96 110 96 130 91 104 89 129 82 98 87 120 81 94
105 72 83 112 114 74 87 89 106 75 85 86 105 73 84 82 104 69 81
121 70 87 114 150 88 109 112 148 88 108 106 132 82 99 92 121 80 94
114 69 84 111 136 101 119 107 126 91 103 103 125 88 100 90 118 76 90
100 71 81 111 144 94 111 89 118 72 87 86 105 71 82 89 108 69 82
118 76 90 109 141 91 108 100 132 87 102 96 111 79 90 94 110 77 88
118 82 94 112 144 102 116 103 140 94 109 99 132 88 103 94 129 82 98
112 77 89 112 139 89 106 105 111 77 88 96 123 77 92 89 110 67 81
110 69 83 105 118 79 92 100 116 79 91 94 110 70 83 88 107 69 82
114 88 97 81 131 79 96 82 126 76 93 82 128 78 95 80 124 78 93
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PROFORMA 
 
Drugs for obtunding intubation response 
 
Name:      Age:   Sex:  Wt: 
 
ASA:    MPC:     IP No: 
 
Diagnosis:       Procedure: 
 
Premedication:       Inj.glycopyrollate 4µg/kg body wt.  
           Inj.fentanyl 2µ/kg body wt. 2 min before induction  
 
Study drug:             IV bolus  
 
Induction:                Inj.thiopentone 5mg/kg 
   
Intubation:               under succinylcholine 1.5mg/kg body wt. using appropriate      
                                  sized ET tube. 
  
Comparison of HR,SBP,DBP,MAP in study groups 
 
      Study drug 
(                          ) 
 
 
HR SBP DBP MAP  Spo2 
Basal values      
After 
premedication 
     
After study drug 
 
     
Induction 
 
     
Laryngoscopy and  
Intubation 
     
 
1 minute 
     
 
3 minutes 
     
 
5 minutes 
     
 
 
Post operative period:    
 
         Recovery and extubation: 
